These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17076885)

  • 21. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia.
    Gimeno-García AZ; Triñanes J; Quintero E; Salido E; Nicolás-Pérez D; Adrián-de-Ganzo Z; Alarcón-Fernández O; Abrante B; Romero R; Carrillo M; Ramos L; Alonso I; Ortega J; Jiménez A
    Gastroenterol Hepatol; 2016; 39(7):433-41. PubMed ID: 26601990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of using Faecal Immunochemical Testing (FIT) as an initial diagnostic investigation for patients with lower gastrointestinal symptoms suggestive of malignancy.
    Kearsey CC; Graham C; Lobb HS; Chacko J; Weatherburn R; Rooney PS
    BMC Fam Pract; 2021 May; 22(1):90. PubMed ID: 33980161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between the serum levels of matrix metalloproteinase 9 and colorectal cancer.
    Rašić I; Rašić A; Akšamija G; Radović S; Šehović N
    Med Glas (Zenica); 2017 Aug; 14(2):229-235. PubMed ID: 28644426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
    Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
    Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer.
    Annaházi A; Ábrahám S; Farkas K; Rosztóczy A; Inczefi O; Földesi I; Szűcs M; Rutka M; Theodorou V; Eutamene H; Bueno L; Lázár G; Wittmann T; Molnár T; Róka R
    Br J Cancer; 2016 Mar; 114(7):787-92. PubMed ID: 26908323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial.
    You JJ; Liu Y; Kirby J; Vora P; Moayyedi P
    Trials; 2015 Jul; 16():296. PubMed ID: 26156248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Options for screening for colorectal cancer.
    Atkin W
    Scand J Gastroenterol Suppl; 2003; (237):13-6. PubMed ID: 12797674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mundt MW; Spijker WJ; Bongers EJC; Kuipers EJ; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gut; 2017 Nov; 66(11):1975-1982. PubMed ID: 27507905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial.
    Walker JG; Macrae F; Winship I; Oberoi J; Saya S; Milton S; Bickerstaffe A; Dowty JG; De Abreu Lourenço R; Clark M; Galloway L; Fishman G; Walter FM; Flander L; Chondros P; Ait Ouakrim D; Pirotta M; Trevena L; Jenkins MA; Emery JD
    Trials; 2018 Jul; 19(1):397. PubMed ID: 30045764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the efficacy of screening tests in colorectal cancer by faecal occult blood test--own experience.
    Kozłowski T; Godlewski D; Biczysko M; Grochowalski M; Nelke M; Paszkowski J; Borejsza-Wysocki M; Krokowicz L; Krokowicz P; Banasiewicz T; Drews M
    Pol Przegl Chir; 2011 Aug; 83(8):411-23. PubMed ID: 22166714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychiatric morbidity and screening for colorectal cancer.
    Parker MA; Robinson MH; Scholefield JH; Hardcastle JD
    J Med Screen; 2002; 9(1):7-10. PubMed ID: 11943790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol.
    Wong G; Howard K; Chapman JR; Tong A; Bourke MJ; Hayen A; Macaskill P; Hope RL; Williams N; Kieu A; Allen R; Chadban S; Pollock C; Webster A; Roger SD; Craig JC
    BMC Public Health; 2011 Jun; 11():516. PubMed ID: 21714917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
    Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
    Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
    Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
    Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of double-contrast barium enema in colorectal cancer screening based on fecal occult blood.
    Ciatto S; Castiglione G
    Tumori; 2002; 88(2):95-8. PubMed ID: 12088265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol.
    Clouston K; Katz A; Martens PJ; Sisler J; Turner D; Lobchuk M; McClement S;
    BMC Cancer; 2012 May; 12():182. PubMed ID: 22607726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
    Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
    Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.